Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | CFO, Sec., Treas. | February 26, 2018 | February 27, 2018 |
| Enveric Biosciences, Inc.ENVB · Entity 8193 | Chief Financial Officer | January 19, 2022 | January 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date February 26, 2018 · Filed February 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,127,364 |
Reported balance
After 2018-02-26 transaction · row 1
1 source rowRow 1 · 2018-02-26 · Grant · Acquired 242,060 · Balance 2,127,364 |
| Common StockSEC Table I · non-derivative | Indirectby IRA | 1,355,014 |
Reported balance
Holding disclosure · report date 2018-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,355,014 |
Enveric Biosciences, Inc.
Report date January 19, 2022 · Filed January 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 744,429 |
Reported balance
After 2022-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-19 · Grant · Acquired 744,429 · Balance 744,429 F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. F2: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock.
F2: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2022 Filed Jan 25, 2022 21:57 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantRestricted Stock Units · Derivative | 744,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-002203 · ownership.xml · derivative · entry 1 Ward Carter Julian · CIK 0001467874 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,429 Underlying: Common Stock · 744,429 shares Expires not disclosed F1 · security: Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. F2 · derivative.exercise_price: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. F2 · derivative.exercise_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. F2 · derivative.expiration_date: 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 21:59 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 242,060 | $0.12 | $29,991.23 |
DisclosureSEC source: 0001053369-18-000004 · primary_doc.xml · nonDerivative · entry 1 Ward Carter Julian · CIK 0001467874 · CFO, Sec., Treas. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,127,364 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:41 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantCommon Stock | 133,019 | $0.23 | $29,995.78 |
DisclosureSEC source: 0001053369-17-000004 · primary_doc.xml · nonDerivative · entry 1 Ward Carter Julian · CIK 0001467874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,885,304 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.